1Calabro P,Yeh ET. The pleiotropie effects of statins[ J]. Curr Opin Cardiol,2005,20(6) :541 - 546.
2Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial [ J ]. JAMA, 2001,285 (13) :1711 - 1718.
3Kiyokuni M, Kosuge M, Ebina T, et al. Effects of pretreatment with statins on infarct size in patients with acute myocardial infarction who receive fibrinolytic therapy[J]. Cite J,2009,73(2) :330 -335.
4Lev EI, Komowski R, Vaknin-Assa H, et al. Effect of previous treat- ment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention[J]. Am J Cardiol,2009,103(2) :165 - 169.
5Mulder HJ, Bal ET, Jukema JW, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty ( REGRESS trial) [ J]. Am J Cardiol,2000,86(7 ) :742 -746.
6Mannacio VA, Iorio D, De Amicis V, et al. Effect of rosuvastatin pre- treatment on myocardial damage after coronary surgery:a randomized trial[ J]. J Thorac Cardiovasc Surg ,2008,136 (6) : 1541 - 1548.
7Raina A, Pickering T, Shimbo D. Statin use in heart failure:a cause for concern? [J]Am Heart J,2006,152( 1 ) :39 -49.
8Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure[ J ]. Circulation ,2006, 113(8) : 1086 - 1092.
9Kjekshus J,Dunselman P,Blideskog M,et al. A statin in the treat- ment of heart failure? Controlled rosuvastafin multinational study in heart failure (CORONA) : study design and baseline characteristics [ J]. Eur J Heart Fail,2005,7(6) :1059 -1069.
10Kjekshus J,Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure[ J]. N Engl J Med,2007,357 (22) : 2248 - 2261.
7Lal MA, Brismar H, Eklof AC, et al Role of oxidative stress in advanced glycation end producation-induced mesangial cell activation [ J]. Kidney Int,2002,61 (6) :2 006-2 014.
8Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells [ J ]. Clin Invest ,2003,112 (7) : 1 049- 1 057.
9Oberg BP, McMenamin E, Lucas FL, et al Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease [ J ]. Kidney Int, 2004,65 ( 3 ) : 1 009-1 016.
10Nihikawa T, Edelstein D, Du XL, et al Normalizing mitochondrial superoxide production blocks three pathways of hyperglycemic damage[J ].Nature, 2002,404 ( 679 ) : 787 -790.
